ArticleDermatology and therapy2025

Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.

Gianluca Avallone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.